You are here

P&T® Journal contents for February 2008


Editor’s Memo
We know you’re as sick of the word “change” as we are, but like many clichés, it serves its purpose. Oh, and by the way, P&T is going digital.
Sonja Sherritze
Given the association between the use of aprotinin (Trasylol) and an increased risk of adverse events among cardiothoracic surgery patients, in contrast to a lack of elevated risk for aminocaproic acid and tranexamic acid, the authors suggest that hospitals examine their current patterns of use and perhaps restrict aprotinin for these patients to prevent major blood loss.
Karl Matuszewski, MS, PharmD; Robert Schoenhaus, PharmD; Mary Ellen Bonk, PharmD; James Lane, PharmD; and Michael Oinonen, PharmD, MPH
The authors describe a study in which they sought to determine whether ­standard practice guidelines for the care of patients with VTE were being ­followed at their VA center.
Cristin Williams, PharmD, Ji Koo, PharmD, and Jonathan Hass, PharmD
Meeting Highlights
Presentations cover lenalidomide (Revlimid) in the treatment of multiple myeloma, eculizumab (Soliris) for paroxysmal nocturnal hemolysis, RAD001 (Everolimus) for lymphoma, the use of deferasirox (Exjade) in patients with iron overload, and dasatinib (Sprycel) and nilotinib (Tasigna) for chronic myelogenous leukemia.
Walter Alexander
Topics include sapropterin dihydrochloride tablets (Kuvan) for reducing phenyl­alanine levels in patients with phenylketonuria; nebivolol (Bystolic) for hyper­tension; and a starch infusion (Voluven) to prevent decreased blood volume ­during surgery.
Marvin M. Goldenberg, PhD, RPh, MS


David Nash, MD, MBA, discusses the challenges and benefits of “mobile social networking” in the digital age of constant connectedness and its potential effect on the future of medicine.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, reports on the problems involved when lidocaine is added to IV potassium chloride.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas details the problems that might arise if drug manufacturers are permitted to market drugs for off-label purposes, especially antipsychotic agents, and the concerns of Congress that clinical trials will be lacking to support the new indications.
Stephen Barlas
From aliskiren to Welchol, P&T presents the latest information on FDA approvals, indications, and industry updates.
Drug Forecast
Authors Cromer and Peker review aliskiren (Tekturna) for hypertension.
Julie Cromer, PharmD, and Simona Peker, BS, MS/MLS, MSA, PharmD